NEW YORK, Jan. 31, 2024 /PRNewswire/ — The hematopoietic stem cells transplantation (HSCT) market size is estimated to increase by USD 2.38 billion from 2023 to 2027, with a CAGR of 6.5%, according to the recent market study by Technavio. This report also offers a 5-year historical (2017-2021) data projection of market size, segmentation, and region. North America will contribute 40% to the growth during the forecast period. The US dominates the Hematopoietic Stem Cells Transplantation (HSCT) market in North America, owing to heightened awareness of stem cell therapy and advanced healthcare infrastructure. Stringent regulations notwithstanding, the prevalence of bone marrow diseases and various blood carcinomas drives market growth. Mixed financing arrangements in healthcare further bolster the expansion in the US, contributing to overall growth prospects in North America. Discover some insights on the size before buying the full report – Request a sample report
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak. The Bargaining Power of Buyers & Suppliers and the Threat of New Entrants, Rivalry, and Substitutes have also been analyzed and rated between LOW-HIGH to provide a holistic view of market favorability.
The report also offers information on the criticality of inputs, R&D, CAPEX, technology, and products of 15 vendors listed Below –
Athersys Inc., Beike Biotechnology Co. Ltd., bluebird bio Inc., Cellular Biomedicine Group Inc., FUJIFILM Corp., Gamida Cell Ltd., Lineage Cell Therapeutics Inc., Lonza Group Ltd., MEDIPOST Co. Ltd., Merck and Co. Inc., Mesoblast Ltd., Pluristem Therapeutics Inc., Sanofi SA, Sartorius CellGenix GmbH, Taiga Biotechnologies Inc., Takeda Pharmaceutical Co. Ltd., Talaris Therapeutics Inc., ThermoGenesis Holdings Inc., AllCells Corp.
The market is segmented by Application (Bone marrow transplant, Peripheral blood stem cell transplant, and Cord blood transplant), Type (Autologous HSCT and Allogeneic HSCT), and Geography (North America, Europe, Asia, and Rest of World (ROW))
- The report is segmented by application into bone marrow transplant, peripheral blood stem cell transplant, and cord blood transplant. The bone marrow transplant sub-segment leads in the growth.
To procure the data – Buy report!
Advancements in hematopoietic stem cells transplantation (HSCT) technology, such as Ranfac’s Marrow Cellution, have led to safer procedures and improved success rates. These innovations address challenges associated with traditional transplant syringes, like contamination and poor cellular yield, driving market growth. Continued technological advancements are expected to fuel adoption rates and expand the global HSCT market during the forecast period.
Growing demand for personalized medicine is an emerging trend fueling the growth, however, the increased risk of complications post-HSCT challenges the growth.
For Insights on the market dynamics & segmentations VIEW A PDF SAMPLE !
What are the key data covered in this report?
- CAGR during the forecast period
- Detailed information on factors that will drive the growth between 2023 and 2027
- Precise estimation of the size and its contribution to the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of vendors
Applications include:
The industry encompasses various procedures like bone marrow, stem cell, and umbilical cord blood transplants, used in conditions like leukemia and lymphoma. Stem cell harvesting and immunosuppression are vital components, with considerations for graft-versus-host disease (GVHD) and engraftment. Donor selection and HLA matching are crucial, alongside post-transplant care and infection management, highlighting the role of transplantation centers and cord blood banks. Ongoing research drives advancements in HSCT.
Technavio’s SUBSCRIPTION platform
Related Reports:
The topical corticosteroids market size is estimated to grow at a CAGR of 4% between 2022 and 2027. The size is forecast to increase by USD 1,089.66 million.
The atopic dermatitis drugs market size has the potential to grow by USD 4,720.19 million during 2023-2027, and the growth momentum will accelerate during the forecast period.
About US
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging trends and provide actionable insights to help businesses identify opportunities and develop effective strategies to optimize their positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable insights to identify opportunities in existing and potential markets and assess their competitive positions within changing scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/hsct-market-to-record-growth-of-usd-2-38-billion-between-2022-and-2027–north-america-to-occupy-40-market-share—technavio-302048280.html
SOURCE Technavio
